Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder

OBJECTIVE: We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. METHODS: A total of 45 BID patients we...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Dong-Hwan, Pae, Chi-Un, Drago, Antonio, Mandelli, Laura, De Ronchi, Diana, Patkar, Ashwin A., Paik, In Ho, Serretti, Alessandro, Kim, Jung-Jin
Formato: Texto
Lenguaje:English
Publicado: Korean Neuropsychiatric Association 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796018/
https://www.ncbi.nlm.nih.gov/pubmed/20046352
http://dx.doi.org/10.4306/pi.2008.5.2.102
Descripción
Sumario:OBJECTIVE: We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. METHODS: A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (±19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C). RESULTS: There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. CONCLUSION: Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.

Ejemplares similares